FARE - Food Allergy Research & Education Logo

A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab

Study Purpose

The purpose of this study to evaluate the potential for disease-mediated drug-drug interactions between cendakimab and selected substrates of metabolic enzymes in eosinophilic esophagitis participants.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years - 75 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Active Eosinophilic esophagitis (EoE) with histologic evidence as a peak count of ≥ 15 eosinophils per higher-power field at any 2 levels of the esophagus.
  • - Previously received an adequate trial of proton-pump inhibitor medication that did not provide complete response to EoE.
  • - EoE symptoms documented in daily diary during the screening period.

Exclusion Criteria:

  • - On a regimen of therapeutic anticoagulation.
  • - Demonstrates evidence of immunosuppression or is receiving systemic immunosuppressive or immunomodulating drugs.
  • - Currently receiving a high potency topical corticosteroid for dermatologic use.
Other protocol-defined inclusion/exclusion criteria apply

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT05175352
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 1
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Celgene
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Bristol-Myers Squibb
Principal Investigator Affiliation Bristol-Myers Squibb
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Eosinophilic Esophagitis
Study Website: View Trial Website
Arms & Interventions

Arms

Experimental: Administration of Cendakimab and Cytochrome P450 (CYP) substrates

Interventions

Drug: - Cendakimab

Specified dose on specified days

Drug: - CYP substrates

Specified dose on specified days

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Del Sol Research Management, Tucson, Arizona

Status

Recruiting

Address

Del Sol Research Management

Tucson, Arizona, 85715

Site Contact

Bassel Kisso, Site 004

Clinical.Trials@bms.com

520-318-1236

GastroIntestinal Biosciences, Los Angeles, California

Status

Recruiting

Address

GastroIntestinal Biosciences

Los Angeles, California, 90067

Site Contact

Nicholas Karyotakis, Site 001

Clinical.Trials@bms.com

310-766-2079

SDG Clinical Research, Inc., San Diego, California

Status

Recruiting

Address

SDG Clinical Research, Inc.

San Diego, California, 92103-5639

Site Contact

Sajiv Chandradas, Site 022

Clinical.Trials@bms.com

855-907-3286

Peak Gastroenterology Associates, Colorado Springs, Colorado

Status

Withdrawn

Address

Peak Gastroenterology Associates

Colorado Springs, Colorado, 80920

Connecticut Gastroenterology Institute, Bristol, Connecticut

Status

Recruiting

Address

Connecticut Gastroenterology Institute

Bristol, Connecticut, 06010-5142

Site Contact

Salam Zakko, Site 016

Clinical.Trials@bms.com

860-585-3838

Nature Coast Clinical Research LLC, Inverness, Florida

Status

Recruiting

Address

Nature Coast Clinical Research LLC

Inverness, Florida, 34452

Site Contact

Siddharth Mathur, Site 002

Clinical.Trials@bms.com

352-341-2100

Homestead Associates in Research Inc, Miami, Florida

Status

Withdrawn

Address

Homestead Associates in Research Inc

Miami, Florida, 33032

A Plus Research Inc, Miami, Florida

Status

Recruiting

Address

A Plus Research Inc

Miami, Florida, 33144-2035

Site Contact

Carlos Ramos, Site 010

Clinical.Trials@bms.com

523-618-9362

Asthma, Allergy Care Center of Florida, Plantation, Florida

Status

Recruiting

Address

Asthma, Allergy Care Center of Florida

Plantation, Florida, 33324-3345

Site Contact

Shahnaz Fatteh, Site 021

Clinical.Trials@bms.com

954-723-0334

Gurnee, Illinois

Status

Recruiting

Address

Illinois Gastroenterology Group- Gurnee (GI Allian

Gurnee, Illinois, 60031-5711

Site Contact

Jonathan Rosenberg, Site 020

Clinical.Trials@bms.com

847-244-2960

University Of Iowa Hospitals And Clinics, Iowa City, Iowa

Status

Recruiting

Address

University Of Iowa Hospitals And Clinics

Iowa City, Iowa, 52242

Site Contact

Rami El Abiad, Site 008

Clinical.Trials@bms.com

855-907-3286

University Of Kansas Medical Center, Westwood, Kansas

Status

Withdrawn

Address

University Of Kansas Medical Center

Westwood, Kansas, 66205

University Of Louisville, Louisville, Kentucky

Status

Withdrawn

Address

University Of Louisville

Louisville, Kentucky, 40202

Albuquerque, New Mexico

Status

Recruiting

Address

New Mexico Clinical Research and Osteoporosis Center

Albuquerque, New Mexico, 87106-4725

Site Contact

Lance Rudolph, Site 003

Clinical.Trials@bms.com

505-855-5505

New York, New York

Status

Withdrawn

Address

Columbia Presbyterian Medical Center (Cpmc)

New York, New York, 10032

SUNY Upstate Medical University, Syracuse, New York

Status

Withdrawn

Address

SUNY Upstate Medical University

Syracuse, New York, 13210

Duke University Medical Center, Durham, North Carolina

Status

Withdrawn

Address

Duke University Medical Center

Durham, North Carolina, 27710

Duke University Medical Center, Durham, North Carolina

Status

Recruiting

Address

Duke University Medical Center

Durham, North Carolina, 27710

Site Contact

David Leiman, Site 018

Clinical.Trials@bms.com

919-668-7924

Optimed Research Ltd, Columbus, Ohio

Status

Recruiting

Address

Optimed Research Ltd

Columbus, Ohio, 43235

Site Contact

Donald McNeil, Site 012

Clinical.Trials@bms.com

614-505-3030

Vanderbilt University Medical Center, Nashville, Tennessee

Status

Withdrawn

Address

Vanderbilt University Medical Center

Nashville, Tennessee, 37232-6307

Houston Endoscopy and Research Center, Houston, Texas

Status

Withdrawn

Address

Houston Endoscopy and Research Center

Houston, Texas, 77079

University of Utah Health Care, Salt Lake City, Utah

Status

Withdrawn

Address

University of Utah Health Care

Salt Lake City, Utah, 84132

McGuire Veterans Affairs Medical Center, Richmond, Virginia

Status

Withdrawn

Address

McGuire Veterans Affairs Medical Center

Richmond, Virginia, 23249

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.